Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Impax Gains Products In Watson Deal With FTC To Finalize Arrow Acquisition

Executive Summary

By stepping in to help Watson Pharmaceuticals avoid antitrust problems in its acquisition of Arrow Group, Impax Laboratories has added cabergoline, the generic of Pfizer's Dostinex for Parkinson's Disease to its portfolio, as well as a pending ANDA for dronabinol, the generic of Solvay Pharmaceutical's Marinol for treating side effects of chemotherapy

You may also be interested in...



Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products

The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.

Watson Acquires Arrow Group And Expands Its Global Footprint

Watson is eying partnerships to further expand branded and generics, but no major deals expected in near term, execs say.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel